Background

Allergen immunotherapy (AIT) is a promising treatment for allergic disease that induces immunological tolerance through the administration of specific allergens. The study of AIT is in its early stage and its clinical effects are not well elucidated. The present study was aimed at determining the effect of AIT on pulmonary function and serum variables of mild allergic asthma patients.

Methods

A total of 80 patients with mild allergic asthma were recruited for the study. Allergen Specific Immunotherapy was administered in the form of Sublingual Immunotherapy and consisted of a build up phase followed by a maintenance phase (six months each respectively). Total serum IgE and vitamin D levels were quantified by ELISA. The percent eosinophill count was determined by cell analyzers. Pulmonary function test was performed at the baseline and after the end of study period. Subjective symptom score was recorded in the form of asthma control questionnaire score.

Results

There was a significant increase in the pre FEV1% and pre FEV1/FVC post AIT administration. A significant decrease in the total serum IgE was found post AIT. A decrease in Asthma control Questionnaire (ACQ) scores indicated an improvement in clinical symptoms. Besides there was a significant effect on ICS discontinuation after AIT.

Conclusion

The study supports SLIT as an effective treatment for Immunomodulation in mild allergic asthmatics besides it gives us significant information regarding the safety and efficacy of SLIT in such patients.

中文翻译：

---

作为轻度过敏性哮喘患者药物治疗的辅助手段，舌下免疫疗法 (SLIT) 1 年后肺功能测试 (PFT) 得到改善

背景

过敏原免疫疗法 (AIT) 是一种有前途的过敏性疾病治疗方法，它通过施用特定的过敏原来诱导免疫耐受。AIT的研究尚处于早期阶段，其临床效果尚未得到很好的阐明。本研究旨在确定 AIT 对轻度过敏性哮喘患者肺功能和血清变量的影响。

方法

该研究共招募了 80 名轻度过敏性哮喘患者。过敏原特异性免疫疗法以舌下免疫疗法的形式进行，包括建立阶段和维持阶段（分别为六个月）。通过ELISA定量总血清IgE和维生素D水平。嗜酸性粒细胞计数百分比由细胞分析仪确定。在基线和研究期结束后进行肺功能测试。主观症状评分以哮喘控制问卷评分的形式记录。

结果

AIT 给药后的前 FEV1% 和前 FEV1/FVC 显着增加。AIT 后发现总血清 IgE 显着降低。哮喘控制问卷 (ACQ) 分数的降低表明临床症状有所改善。此外，AIT 后停用 ICS 也有显着影响。

结论

该研究支持 SLIT 作为轻度过敏性哮喘患者免疫调节的有效治疗方法，此外它还为我们提供了有关 SLIT 在此类患者中的安全性和有效性的重要信息。